Liquidia

Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of novel products utilizing its proprietary PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that has completed Phase III clinical trial for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865 for the treatment of local post-operative pain that is in Phase II-enabling toxicology studies. It has collaboration agreements with GlaxoSmithKline plc and the University of North Carolina. Liquidia Technologies, Inc. was founded in 2004 and is headquartered in Morrisville, North Carolina.